A signal-enhanced and sensitive lateral flow aptasensor for the rapid detection of PDGF-BB

Cheng, Na; Liu, Yujie; Mukama, Omar; Han, Xiaobo; Huang, Haowen; Li, Shuai; Zhou, Peng; Lu, Xuewen; Li, Zhiyuan

doi:10.1039/d0ra02662j

Cited by 10 publications

(9 citation statements)

References 41 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, aptamers have been extensively studied as biorecognition molecules for LFAs. In these studies, various signal amplification strategies, such as enzyme amplification, magnetic enrichment, modification of gold nanoparticles, and integration with isothermal amplification, have been exploited [113][114][115][116]. Therefore, this strategy can be fully utilized for diagnosing COVID-19, and the aptamer-based COVID-19 LFA technology will become more mature in the future.…”

Section: Aptamer-based Paper-based Diagnostic Platformmentioning

confidence: 99%

Current Advances in Paper-Based Biosensor Technologies for Rapid COVID-19 Diagnosis

Kim

Lee

2022

BioChip J

View full text Add to dashboard Cite

The global coronavirus disease 2019 (COVID-19) pandemic has had significant economic and social impacts on billions of people worldwide since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, in November 2019. Although polymerase chain reaction (PCR)-based technology serves as a robust test to detect SARS-CoV-2 in patients with COVID-19, there is a high demand for cost-effective, rapid, comfortable, and accurate point-of-care diagnostic tests in medical facilities. This review introduces the SARS-CoV-2 viral structure and diagnostic biomarkers derived from viral components. A comprehensive introduction of a paper-based diagnostic platform, including detection mechanisms for various target biomarkers and a COVID-19 commercial kit is presented. Intrinsic limitations related to the poor performance of currently developed paper-based devices and unresolved issues are discussed. Furthermore, we provide insight into novel paper-based diagnostic platforms integrated with advanced technologies such as nanotechnology, aptamers, surface-enhanced Raman spectroscopy (SERS), and clustered regularly interspaced short palindromic repeats (CRISPR)-Cas. Finally, we discuss the prospects for the development of highly sensitive, accurate, cost-effective, and easy-to-use point-of-care COVID-19 diagnostic methods.

show abstract

Section: Aptamer-based Paper-based Diagnostic Platformmentioning

confidence: 99%

Current Advances in Paper-Based Biosensor Technologies for Rapid COVID-19 Diagnosis

Kim

Lee

2022

BioChip J

View full text Add to dashboard Cite

show abstract

“…These complexes then flow to the conjugation zone where the biotinylated aptamer-target conjugate binds to a detection antibody complex or the free target binds to a capture aptamer-labelled SERS tag. Streptavidin or streptavidin-conjugated biotinylated detection aptamers are immobilized on the test zone, to which the aptamer: target complexes flow and bind, which can be visualized instantly due to the presence of reporter molecules (Cheng et al, 2020;Cao et al, 2021). The dotted lines in the figure depict the different studies that have used similar bio-sensing principles.…”

Section: Biosensors: Evolving Tools For Detection Of Disease-specific...mentioning

confidence: 99%

“…Platelet-derived growth factor (PDGF) promotes cancer development and progression by modulating cell growth, angiogenesis, metastasis and apoptosis. Increased expression of PDGF has been observed in breast cancer (Ariad et al, 1991) and esophageal cancer (Krzystek-Korpacka et al, 2011) Several groups have independently developed lateral flow aptasensors (LFAs) for the detection of PDGF in spiked serum samples (Liu et al, 2019) or patient sera (Cheng et al, 2020;Cao et al, 2021). LFAs have gained attention owing to their rapid, cost-effective and userfriendly properties.…”

Section: Biosensor-based Detection Of Cytokines In Cancer Patient-der...mentioning

confidence: 99%

“…The antibodies that did not bind to PDGFaptamer complexes migrate forward and are captured by the polyclonal anti-mouse antibodies immobilized on the control line. This biosensor exhibited a DL of 1 ng/mL in an assay time of 10 min (Cheng et al, 2020) (Figure 2C). The organization of the LFA was further improved by including a SERS-tag in the conjugate pad leading to lower DL (3.802 pg/mL) for PDGF-BB (Cao et al, 2021).…”

Section: Biosensor-based Detection Of Cytokines In Cancer Patient-der...mentioning

confidence: 99%

See 1 more Smart Citation

Sensing Soluble Immune Checkpoint Molecules and Disease-Relevant Cytokines in Cancer: A Novel Paradigm in Disease Diagnosis and Monitoring

et al. 2022

View full text Add to dashboard Cite

Conventional detection of cancer involves highly invasive and expensive diagnostic procedures, often leading to non-compliance from patients. Therefore, there is a strong requirement for the development of non-invasive techniques that can facilitate rapid and timely diagnosis of the disease. The tumor-immune interaction often leads to anomalous expression of different soluble immune signaling molecules like cytokines and chemokines, thus making them promising candidates for sensing disease development and progression. Furthermore, differential expression of soluble isoforms of several immune-checkpoint molecules like PD-L1, CTLA-4 etc., has been found to have strong correlation with tissue-specific tumor development, disease progression and in many cases, disease prognosis. Therefore, development of biosensors, to rapidly detect and analyze the levels of these soluble immune molecules in different body fluids, requiring minimal sample volume, has the potential to be a game-changer in the field of cancer diagnosis. In addition, real time monitoring of these soluble immune checkpoint molecules in patient-derived biofluids may serve as decision support tools for patient selection for immunotherapeutic interventions. Majority of the biosensors designed to detect the soluble immune biomarkers, have used a two-antibody based sandwich system to capture the target analyte. However, new technologies using bioreceptors like the aptamers or nano-yeast scFv antibody fragments have made possible multiplexed detection of several analytes simultaneously. The use of gold nanoparticles or carbon nanotubes on the electrode surface serves to increase the sensitivity of detection, due to their high electrical conductivity. Further, fabrication of the biosensors on microfluidic platforms enable the detection of these analytes at ultra-low levels. This review discusses the recent advances made in the development of biosensors for specific and selective detection of these immune-markers that can be successfully translated to the clinics as a new paradigm in disease diagnosis and monitoring.

show abstract

“…Concurrently, the recognition capability of antibodies suitable for antigens measuring respective antigens when antibodies are assayed is frequently replaced by the use of aptamers by many assays. Extensive progress in aptamer preparation has been reached in recent years, and the aptamers typically comprise ribonucleic acid (RNA), deoxyribonucleic acid (DNA), peptides, or proteins [42][43][44][45][46][47][48].…”

Section: Current Trends In Lft Construction In Point-of-care Diagnosismentioning

confidence: 99%

Point-of-Care Diagnoses and Assays Based on Lateral Flow Test

Pohanka

2021

International Journal of Analytical Chemistry

View full text Add to dashboard Cite

Analytical devices for point-of-care diagnoses are highly desired and would improve quality of life when first diagnoses are made early and pathologies are recognized soon. Lateral flow tests (LFTs) are such tools that can be easily performed without specific equipment, skills, or experiences. This review is focused on the use of LFT in point-of-care diagnoses. The principle of the assay is explained, and new materials like nanoparticles for labeling, new recognition molecules for interaction with an analyte, and new additional instrumentation like signal scaling by a smartphone camera are described and discussed. Advantages of the LFT devices as well as their limitations are described and discussed here considering actual papers that are properly cited.

show abstract

A signal-enhanced and sensitive lateral flow aptasensor for the rapid detection of PDGF-BB

Abstract: Platelet-derived growth factor BB (PDGF-BB) is a potential biomarker of tumor angiogenesis.

Cited by 10 publications

References 41 publications

Current Advances in Paper-Based Biosensor Technologies for Rapid COVID-19 Diagnosis

Current Advances in Paper-Based Biosensor Technologies for Rapid COVID-19 Diagnosis

Sensing Soluble Immune Checkpoint Molecules and Disease-Relevant Cytokines in Cancer: A Novel Paradigm in Disease Diagnosis and Monitoring

Point-of-Care Diagnoses and Assays Based on Lateral Flow Test

Contact Info

Product

Resources

About